C2N Diagnostics, LLC, headquartered in the United States, is a pioneering company in the field of diagnostic testing, particularly focused on neurodegenerative diseases. Founded in 2012, C2N has established itself as a leader in the development of innovative biomarkers that aid in the early detection and management of conditions such as Alzheimer’s disease. The company’s flagship products, including the PrecivityAD™ test, are designed to provide clinicians with critical insights into patients' cognitive health, setting C2N apart in the competitive diagnostics landscape. With a commitment to advancing precision medicine, C2N Diagnostics has achieved significant milestones, including partnerships with leading research institutions and recognition for its contributions to the field. As a trusted name in neurodiagnostics, C2N continues to enhance patient care through its cutting-edge solutions.
How does C2N Diagnostics, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
C2N Diagnostics, LLC's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
C2N Diagnostics, LLC, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and commitments suggests that C2N Diagnostics may not yet have established a formal framework for measuring or reducing its carbon footprint. In the context of the diagnostics industry, many companies are increasingly adopting science-based targets and sustainability initiatives to address climate change. However, without specific commitments or data, C2N Diagnostics remains outside this trend. As the industry evolves, it may be beneficial for the company to consider implementing strategies to monitor and reduce its environmental impact.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
C2N Diagnostics, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.